Wednesday, September 19, 2012
Folliculitis
Folliculitis
Localized inflammation of a hair follicle. The condition may be caused by infections, injury or irritation and is generally found on the face, neck, breast and buttocks. The damaged follicles are then infected with the bacteria Staphylococcus (staph).
The condition may be caused by staph aureus, yeast or fungi. If the condition spreads or becomes persistent swab cultures may need to be taken.
Lymphedema patients are more susceptible to skin infections and are strongly advised against hot tubs because of the possibility of contracting Pseudomona folliculitis. This is a resistant gram-negative bacterial infection with serious complications. Barber's itch is a staph infection of the hair follicles in the beard area of the face, usually the upper lip. Shaving makes it worse. Tinea barbae is similar to barber's itch, but the infection is caused by a fungus.
Pseudofolliculitis barbae is a disorder that occurs mainly in black men. If curly beard hairs are cut too short, they may curve back into the skin and cause inflammation.
Clinical:
Pus in the hair follicle
Irritated and red follicles
Damaged hair (possibly in growing back into the follicle)
Complications:
While we tend to think of folliculitis as a minor and superficial infection, it is important to remember that with a lymphedema limb that is immunocompromised, the folliculitis could develop into a more severe infection. Complications include cellulitis, forunculosis (This condition occurs when a number of boils develop under your skin. Boils usually start as small red bumps but become larger and more painful as they fill with pus), scarring, destruction of the hair follicle. Untreated and/or severe/deep folliculitis could result in sepsis and bacteremia.
Treatment:
Topical antibiotics which may include bacitracin, polymyxin B sulfate (Polysporin), clindamycin, erythromycin, or mupirocin (Bactroban). You may also use an antiseptic cleanser, such as povidone-iodine (for example, Betadine) or chlorhexidine.
Oral antibiotics based on the seriousness (deeper or more severe infections) of the folliculitis or on the underlying medical condition of the patient. If caused by a bacteria, your doctor may prescribe dicloxacillin, erythromycin, or cephalexin (such as Keflex). Ciprofloxacin (Cipro) and ofloxacin (such as Floxin) are used for certain types of bacteria.
Fungus based folliculitis is treated with antifungal oral medications which include You will need to take antifungal pills, such as fluconazole (Diflucan), griseofulvin (Fulvicin-U/F or Gris-PEG, for example), itraconazole (Sporanox), or terbinafine (Lamisil).
Full Text Page
Erysipelas
Key Words: Strep A, Lymphedema, Cellulitis, Bacteremia, Septicemia, Cutaneous lympatics, immunocompromised, St. Anthony's Fire, Staph aureus, Strep G, Penicillin, Probenecid, Dicloxacillin, Erythromycin, Keflex, Augmentin, Necrosis, Gangrene, Thrombophebitis, Bacterial endocarditis, Soft tissue infections
Discussion
Erysipelas (also called St. Anthony's Fire)is a superficial bacterial skin infection skin generally caused by (Strep A bacteria or Strep B bacteria. It can spread with alarming rapidity as it invades the cutaneous lymphatics.
While some classify it as a "form of cellulitis," it actually can be differentiated by the clear lines of demarcation of the infection. Symptoms include marked lines of infection, fever, pain, an overall achy feeling and swollen lymph nodes. Most cases involve the legs, and the second largest number of cases involve the face. However a delay in treatment can result in deeper cellulitis or lymphangitis.
Like any type of infection a lymphedema patient experiences, antibiotic treatment needs to start immediately so as to prevent septicemia or bacteremia. As with any infection erysipelas present a serious threat due to the immunocompromised state of the lymphedemous limb and because possible fibrosis handicaps effective antibiotic therapy. Also, in lymphedema patients Staph aureus (not Strep A) has been implicated as the infective bacteria.
While very similar and often confused with actual cellulitis it can be differentiated by the raised borders and advancing edges. The most commonly affected body areas are the legs, followed by the face.
Risk Factors
There are a number of factors that might predispose one to erysipelas. The primary cause of course is a break, cut or entry foci in the skin and subsequent infection usually by a Strep A bacterium. Susceptibility factors include edema, lymphedema, venous insufficiency, venous stasis, dermatosis, diabetes, HIV infection, and other immunocompromising medical conditions.
Transmission factors include port of entry through nasal cavity, insect bites, cut, incisions.
Symptoms
The infection may start out as a inconspicuous small red patch and spread rapidly to a painful fiery red plaque. The infection area will be warm or hot and quite tender. Over-all body symptoms might include feeling unusually drained of energy, achiness, chills, fever and malaise. There may also be blisters on the infected area and possible red streaking.
Treatment
Treatment generally will involve the administration of an oral antibiotic. The infection responds well to penicillin based antibiotic. In addition Probenecid may be used as it increase the effectiveness of penicillins. For more resistant infections dicloxacillin may be used. Other antibiotics may include Nafcillin, Erythromycin, Keflex and Augmentin.
Depending upon the severity and spread IV antibiotic therapy may also be used for lymphedema patients. Also, limiting one's activity with limb elevation is standard protcol.
Blood cultures and/or wound cultures may be needed to determine the exact bacteria involved.
Complications
Complications may include bacteremia or septicemia, abscess, tissue necrosis (gangrene)in the most severe cases, thrombophlebitis, bacterial endorcarditis.
Prognosis
Prompt diagnosis and treatment will bring favorable results and in all but a very few patients recovery will be complete and without complications. At risk groups, including those with lymphedema may experience recurrent episodes.
Full Text
Wednesday, August 29, 2012
What are fungal infections of the nails
Four Key Features of a Fungus
Lymphedema and Preventing Fungal Infections
Not every infection we get as lymphedema patient is due to a bacterial "invasion."
We can also very quickly come down with a fungal infection. Due to the immunocompromised condition of the lymphedema limb, this fungus may literally explode over the limb before we even know what hit us.
It is critical that we know:
How to Prevent Fungal Infections
Monday, March 5, 2012
Hizentra Cuts Infections in Immune Disorders
Hizentra Cuts Infections in Immune Disorders
ORLANDO -- Subcutaneous immune globulin (Hizentra) remains safe and effective up to two years in the treatment of patients with primary immunodeficiency diseases, researchers reported here.
The overall rate of infections was 2.4 per patient-year (95% CI 1.9 to 2.9) among patients receiving once-weekly infusions of the subcutaneous immune globulin, according to Robert P. Nelson, Jr., MD, of Indiana University in Indianapolis, and colleagues.
And the rate of serious bacterial infections was 0.06 per patient-year, which consisted of two cases of bacterial pneumonia, the researchers reported in a poster session at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.
Conventional therapy for conditions such as common variable immunodeficiency or X-linked agammaglobulinema has been monthly infusions of intravenous immune globulin.
The treatment is needed lifelong to prevent patients from recurrent bacterial infections and chronic pulmonary disease.
In a previous shorter-term study (52 weeks), the subcutaneous route of delivery was associated with fewer systemic adverse events than the intravenous formulation.
"The weekly subcutaneous treatment leads to stable serum IgG levels, and smooths out the peaks and troughs," Nelson told MedPage Today during a poster session.
To assess longer-term outcomes, he and his colleagues followed 21 patients from four U.S. centers from 11 to 104 weeks. Most patients were white women, and their mean age was 42.
Patients who had lymphoid malignancies, hypoalbuminemia, and proteinuria were excluded from the study.
Maximum infusion rates were 35 mL/h (one pump) or 70 mL/h (two pumps) with the maximum volume being 40 mL/site (≤4 sites/infusion). Premedication was not given.
]Most infusion were given at home and self-administered. The median duration of treatment was 87 weeks.
Five patients withdrew but only one because of an adverse event, which was thyroid cancer unrelated to treatment.
Adverse event and local reaction rates were similar among subjects infused at low (<35 mL/h), medium (35-50 mL/h), and high (>50-70 mL/h) rates.
The most common infections were sinusitis, nasopharyngitis, bronchitis, and upper respiratory tract infections.
The annual rate of school or work days lost because of infection was 4.3 per patient-year, while the rate of hospitalized days was 0.55 per patient-year.
The rate of days on antibiotics for prophylaxis or treatment was 84 per patient-year.
Mean serum IgG levels remained steadily in the range of 11.71 g/L and 12.76 g/L throughout the follow-up period.
Treatment-related adverse events occurring within 72 hours of the infusion included headache, at an incidence of 0.004 events per patient-year, and fatigue, at a rate of 0.005 per patient-year.
Headache tends to occur more frequently with intravenous administration, the investigator said.
No patients experienced oropharyngeal pain or had an increase in creatinine.
Infusion reactions were similar regardless of whether patients had low, medium, or high infusion rates.
The rate of any temporally associated, treatment-related adverse events was 0.013 per patient year, which was "substantially lower" than in a previous study (0.034), despite higher mean infusion rates being used in this longer follow-up trial, Nelson reported.
Patient satisfaction was high, with overall scores on measures of health being close to those reported by healthy individuals, and there was no clinically significant deterioration in health-related quality of life.
FDA approves breath test to determine bacterial infection in kids Read more: http://www.foxnews.com/health/2012/02/28/fda-approves-breath-test-to-det
U.S. health regulators have approved Otsuka America Pharmaceutical's breath test to detect bacterial infection that causes stomach inflammation and ulcer, for use in children aged 3 to 17 years.
A press release from the U.S.Food and Drug Administrationsaid BreathTek UBT was the first breath test to detect Helicobacter pylori bacterial infections in children.
Rockville, Maryland-based Otsuka America, a unit of Japan's Otsuka Holdings Co Ltd, was granted approval to market its breath test for use in adults in 1996.
"Results from this test, when considered with a physician's assessment of thepatient'shistory, other risk factors, and professional guidelines, can quickly indicate infection," the FDA release said.
U.S.Centers for Disease Control and Prevention estimate that about two-thirds of the world's population is infected with Helicobacter pylori, which increases the risk of developing gastric cancer and a type of lymphoma.
